Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Black Diamond Therapeutics Q3 2026 Results: Net Loss of $10M, Loss Widens

Black Diamond Therapeutics reported total assets of $115.6 million as of September 30, 2026, a decrease from $143.0 million at year-end 2025. The company is focused on advancing its lead candidate silevertinib toward Phase 3 trials and managing its partnership with Servier Pharmaceuticals for BDTX-4933.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-10.0-8.5
EPS (diluted, $ a share)$-0.17$-0.15

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BDTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Black Diamond Therapeutics, Inc.: key numbers

Share price
$1.53Close, Nov 16
Market cap
$87.9M
Shares outstanding
57.47MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Black Diamond Therapeutics, Inc.

All →
6:29 AM ET 8-K
Financial Results

Black Diamond Therapeutics Financial Results

Black Diamond Therapeutics reported Q3 2026 financial results and updated Phase 2 data for silevertinib in frontline NSCLC, showing an 86% CNS-ORR in patients with brain metastases. The company received FDA feedback supporting a pivotal Phase 3 trial design with potential for accelerated approval. Current cash reserves of $102.0 million are expected to fund operations into the second half of 2028.

Term
Q3 2026

“Our recent end of Phase 2 meeting with the FDA was highly collaborative, and we believe the feedback we received supports a clear path to potential accelerated and full approval for silevertinib in frontline NSCLC patients with EGFR non-classical mutations. This trial design offers a differentiated path to potential accelerated approval in EGFR-NCM patients, who represent about 25% of the frontline EGFR mutant patient population.”

Mark Velleca, M.D., Ph.D., President and Chief Executive Officer

“We believe that silevertinib’s ability to significantly delay CNS progression is the key driver of the durable clinical benefit we are seeing in patients both with and without baseline brain metastases and is the foundation of the pivotal program design in 1L NSCLC.”

Sergey Yurasov, M.D., Ph.D., Chief Medical Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.